The Food and Drug Administration today announced four priority areas for additional policy activity in 2018: reducing addiction to opioid drugs and cigarettes; promoting innovation and competition; empowering consumers to make informed decisions; and strengthening the FDA workforce. Specific policy efforts include new steps to support and streamline development and approval of treatments that address addiction; reducing burdens for creating and approving generic drugs; and extending new hiring and pay authorities to recruit and retain FDA staff.

Related News Articles

Headline
The Substance Abuse and Mental Health Services Administration will launch a three-part virtual learning series on recovery supports for people considering or…
Headline
Drug overdose deaths declined 5.1% in 2018 to about 68,000, according to preliminary data from the Centers for Disease Control and Prevention.
Headline
Under a new Centers for Medicare…
Headline
The Centers for Medicare…
Headline
Six health care organizations in rural North Carolina communities will share $1.2 million in federal grant funds to strengthen and expand their response to…
Headline
The Food and Drug Administration yesterday released new draft guidance for labeling medications that carry the risk of abuse or dependence, including but not…